ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0247

Rheumatoid Arthritis as a Modifier of the Cognition-Daily Function Association

Maria Vassilaki1, Stephanie Duong1, Chanakya Kodishala1, Rabia Javed1, Michelle Mielke2, John Davis1, Cynthia Crowson3 and Elena Myasoedova1, 1Mayo Clinic, Rochester, MN, 2Wake Forest University School of Medicine, Winston-Salem, NC, 3Mayo Clinic, Eyota, MN

Meeting: ACR Convergence 2022

Keywords: rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 12, 2022

Title: RA – Diagnosis, Manifestations, and Outcomes Poster I

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: Instrumental activities of daily living (iADLs) are complex abilities necessary for independent living involving higher cognitive functions and decline earlier than basic (b) ADLs in the dementia course. The cognitive function and iADLs association is not thoroughly understood; motor and physical limitations could interfere with bADLs and iADLs. Patients with rheumatoid arthritis (RA) are at increased risk for functional limitations. The study examined whether having RA modifies the association between cognition and iADLs.

Methods: The study included 104 RA cases and 312 participants without RA (≥40 years old; mean (SD) age: 75 (10.4) years; 33% male; median follow-up: 3.01 (IQR: 1.2, 6.6) years) of a prospective study of cognitive aging in community-dwelling adults, matched 1:3 for age, sex, education, and cognitive status at cognitive aging study baseline. RA cases satisfied the 1987 ACR classification criteria. iADLs were assessed by the informant-based Functional Activities Questionnaire (FAQ), a 10-item scale (range 0-30, a higher score indicates more functional difficulties). We used Kruskal-Wallis rank-sum and Fisher’s exact tests to compare the baseline characteristics between the groups. We used linear mixed-effects models to examine the association between cognitive performance (global cognitive z-score; based on assessment with nine neuropsychological tests) and FAQ score adjusted for age, sex, education, and practice effects. Potential effect modification by RA was examined using an interaction term between cognitive z-score and RA status (yes/no). Estimated coefficients (b) and standard errors (SE) are presented.

Results: Participants with vs. without RA did not differ in age, sex, years of education, or cognitive status, as expected. Informants were less likely to report normal activity for participants with RA vs. without RA in two FAQ items at baseline, i.e., “assemble tax records, business affair, or papers “, (82% vs. 92% normal activity; p=0.024) and “shopping alone for clothes, household necessities, or groceries,” (89% vs. 95% normal activity; p=0.028). There was a borderline statistically significant three-way (i.e., cognitive z-score*time*RA) interaction (p=0.07); we observed that the increase in FAQ score (i.e., worse iADLs) per unit decrease in cognitive function might be greater in participants with RA than without RA; i.e., for every 1-unit decrease in global cognitive z-score, the difference in the annualized rate of change from baseline in the FAQ total score was b (SE)=0.22 (0.05) (p< 0.001) in the group with RA, and b (SE)=0.07 (0.03) (p=0.006) in the group without RA.

Conclusion: There is an inverse association between cognitive measurement and FAQ score over time that could be adversely affected by RA status. Further examination will be helpful to improve our understanding of the implications of these findings on the interpretation of the FAQ results in patients with RA and possible cognitive impairment (CI), especially as RA has been associated with CI in previous reports.


Disclosures: M. Vassilaki, F. Hoffmann-La Roche, Biogen, F. Hoffmann-La Roche, Avobis Bio, LLC., Amgen, Abbott Laboratories, Johnson and Johnson, Medtronic, AbbVie; S. Duong, None; C. Kodishala, None; R. Javed, None; M. Mielke, LabCorp, Biogen; J. Davis, Pfizer; C. Crowson, None; E. Myasoedova, None.

To cite this abstract in AMA style:

Vassilaki M, Duong S, Kodishala C, Javed R, Mielke M, Davis J, Crowson C, Myasoedova E. Rheumatoid Arthritis as a Modifier of the Cognition-Daily Function Association [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/rheumatoid-arthritis-as-a-modifier-of-the-cognition-daily-function-association/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/rheumatoid-arthritis-as-a-modifier-of-the-cognition-daily-function-association/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology